Drug intelligence / Profile preview

SIS029

Development stage: Preclinical
Lead developer: Nanjing Sanhome Pharmaceutical

Overview

SIS029 is a preclinical-stage drug candidate being developed by Nanjing Sanhome Pharmaceutical. It is currently under investigation for the treatment of various solid tumors, including pancreatic cancer, small cell lung cancer, ovarian cancer, and other forms of lung cancer. As a preclinical asset, further details regarding its specific molecular target and modality have not been fully disclosed.

Beyond the preview

Go deeper on SIS029.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIS029.

Explore the full profile